Home Tags Astellas

Tag: Astellas

Potential Accelerated Approval for Enfortumab Vedotin in Combination with Pembrolizumab as...

Updated data from the phase Ib/II multicohort EV-103 trial (NCT03288545; also known as KEYNOTE-869) of enfortumab vedotin* (Padcev™; Seattle Genetics/Astellas Pharma) in combination with...

Accelerated Approval for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial...

The U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma / Seattle Genetics)* for the treatment of adult...
Featured Image: Annual Congress of ESMO 2018. Courtesy: © 2018 European Society for Medical Oncology. Used with permission.

ESMO 2019: Seattle Genetics to Present Initial Data from a Phase...

Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO), to be held September 27...
Astellas Pharma, Exhibition booth during ASCO 2019, held May 31 – June 4, 2019 in Chicago, Ill.| Courtsey: Emila Duaerte / Sunvalley Communication

U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application...

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin, also known as ASG-22CE,...
Featured Image: Doctor explaining diagnosis to her patient Courtesy: © 2017 Fotolia. Used with permission.

Phase Ib Trial of Enfortumab Vedotin + Immune Checkpoint Inhibitor Initiated...

Seattle Genetics and Astellas Pharma confirmed the dosing of the first patient in EV-103, a phase Ib clinical trial evaluating the safety and tolerability...

Winding-Down of Research Operations but Astellas Retains Promising Antibody-Drug Conjugate R&D...

In a surprise move to most, but expected by industry insiders, Astellas Pharma, a Japan-based company focusing on the development of novel treatments in Urology,...

Phase I Data of Enfortumab Vedotin in Metastatic Urothelial Cancer Supports...

Updated phase I data for enfortumab vedotin, also known as ASG-22ME or ASG-22CE , studied as monotherapy treatment for metastatic urothelial cancer (mUC) were...

Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...

Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E,  presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...

Astellas Presents Study-results of two Investigational ADCs in Patients with Metastatic...

With two approved antibody-drug conjugates and a large number of  ADCs in clinical development scientists have made significant advances bringing novel ADC technology to the forefront...